When Australian biotech firm Innate Immunotherapeutics needed to raise money last summer, it offered a sweetheart deal to “sophisticated U.S. investors.” One of them was Rep. Tom Price.
By Jay Hancock and Rachel Bluth, Kaiser Health News
In Congress, lawmakers are close to passing a major bill that would increase funding for the FDA, the NIH and the effort to fight opioid abuse. The measure would also introduce more flexible standards for drug approvals, reducing the need…
By PBS NewsHour
Trump's nominee to be secretary of health and human services, Rep. Tom Price, could have conflicts of his own.
By Sheila Kaplan, STAT
The absence of drug-pricing proposals from the GOP contenders illustrates how hard it would be for Sanders or Clinton to get Congressional approval should they win office.
By Philip Moeller
By Michael Ollove, Stateline
As more expensive specialty drugs come on the market to treat some of the most serious chronic diseases, more states are stepping in to cushion the financial pain for patients who need medicine that can cost up to hundreds of…
By Richard Knox, NPR
A growing number of people who got infected in the 1960s through the 1990s have now "used up" the infection's latency period, notes Dr. Camilla Graham of Beth Israel Deaconess Hospital in Boston, "which is why we're now seeing this…
News Wrap: GlaxoSmithKline to Pay $3 Billion in Fraud Settlement…
NewsHour special correspondent Jeffrey Kaye reports on China's health care reform.
Support Provided By: Learn more